Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96QU1
UPID:
PCD15_HUMAN
Alternative names:
-
Alternative UPACC:
Q96QU1; A6NL19; C6ZEF5; C6ZEF6; C6ZEF7; Q5VY38; Q5VY39; Q6TRH8; Q8NDB9; Q96QT8
Background:
Protocadherin-15 is a calcium-dependent cell-adhesion protein, pivotal for the maintenance of normal retinal and cochlear function. This protein plays a crucial role in the structural and functional integrity of the retina and cochlea, implicating its significance in sensory perception.
Therapeutic significance:
Linked to Usher syndrome types 1F and 1D/F, and autosomal recessive deafness 23, Protocadherin-15 is at the heart of research for genetic hearing and vision disorders. Understanding its role could pave the way for groundbreaking therapies in sensory impairments.